companies

ArcDia / mariPOC

Founded 2008
Employees 20+
Primary contact
Lemminkäisenkatu 32
20520 Turku
Finland
Links
https://www.arcdia.com/
ArcDia develops what it claims to be the most complete in vitro diagnostic solutions for acute infections suitable for decentralized testing of respiratory and gastrointestinal infections such as COVID-19, influenza, RSV, CDI and many more. It provides hospitals, healthcare centers, transportation hubs and workplaces with high-quality tests that are fast, high-throughput and reliable. The company's mariPOC platform is designed for detecting acute and contagious infections, using the sandwich immunoassay principle and two-photon excited fluorescence assay technique — enabling automation, ease-of-use, multianalyte capability, cost-efficiency and high performance.
Founded 2008
Employees 20+
Primary contact
Lemminkäisenkatu 32
20520 Turku
Finland
Links
https://www.arcdia.com/

Funding 💰

Select investors Lifeline Ventures, Finnvera, Innovestor

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the problem: Antibiotic resistance is a growing concern globally, with resistance being responsible for causing 23,000 deaths per year in the US alone. ArcDia's pipeline product portfolio includes mariAST (RUO), a solution for tackling antibiotic resistance by speeding up antimicrobial susceptibility testing.
  • Real-time epidemiological surveillance: ArcDia's mariCloud is an online service for real-time epidemiological surveillance. The tool helps healthcare professionals monitor infection incidence in real time and enables improved pandemic and epidemic preparedness.
  • Available worldwide: As of May 2023, mariPOC diagnostic solutions were available in more than 30 countries. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2014 Frost & Sullivan Award for Point-of-Care Product Leadership 🔗
Last update: May 23, 2023